Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate in children and adolescents with KBG syndrome and ADHD-related symptoms
NL-OMON59031Phase 4Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of methylphenidate in attention deficit hyperactivity disorder (ADHD) and KBG syndrome (KBG), sponsored by Radboud University Medical Center. Primary endpoint: Strengths and Difficulties Questionnaire ADHD subscale. Started Oct 2024; status: recruiting.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)KBG syndrome (KBG)
Beyond the preview
Go deeper on NL-OMON59031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59031.